CN113518823B - 多功能的融合蛋白及其用途 - Google Patents

多功能的融合蛋白及其用途 Download PDF

Info

Publication number
CN113518823B
CN113518823B CN202080016520.5A CN202080016520A CN113518823B CN 113518823 B CN113518823 B CN 113518823B CN 202080016520 A CN202080016520 A CN 202080016520A CN 113518823 B CN113518823 B CN 113518823B
Authority
CN
China
Prior art keywords
ser
val
leu
thr
pro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202080016520.5A
Other languages
English (en)
Chinese (zh)
Other versions
CN113518823A (zh
Inventor
马克·L·泰科辛斯基
马修·C·韦伯
卡梅拉·罗密欧·史密斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Thomas Jefferson University
Original Assignee
Thomas Jefferson University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Thomas Jefferson University filed Critical Thomas Jefferson University
Publication of CN113518823A publication Critical patent/CN113518823A/zh
Application granted granted Critical
Publication of CN113518823B publication Critical patent/CN113518823B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C07K14/522—Alpha-chemokines, e.g. NAP-2, ENA-78, GRO-alpha/MGSA/NAP-3, GRO-beta/MIP-2alpha, GRO-gamma/MIP-2beta, IP-10, GCP-2, MIG, PBSF, PF-4, KC
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202080016520.5A 2019-01-07 2020-01-07 多功能的融合蛋白及其用途 Active CN113518823B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962789212P 2019-01-07 2019-01-07
US62/789,212 2019-01-07
PCT/US2020/012624 WO2020146423A1 (en) 2019-01-07 2020-01-07 Multi-functional fusion proteins and uses thereof

Publications (2)

Publication Number Publication Date
CN113518823A CN113518823A (zh) 2021-10-19
CN113518823B true CN113518823B (zh) 2025-05-02

Family

ID=71521906

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080016520.5A Active CN113518823B (zh) 2019-01-07 2020-01-07 多功能的融合蛋白及其用途

Country Status (12)

Country Link
US (2) US12497439B2 (cg-RX-API-DMAC10.html)
EP (1) EP3908664A4 (cg-RX-API-DMAC10.html)
JP (1) JP7587505B2 (cg-RX-API-DMAC10.html)
KR (2) KR20260116815A (cg-RX-API-DMAC10.html)
CN (1) CN113518823B (cg-RX-API-DMAC10.html)
AU (2) AU2020207265B2 (cg-RX-API-DMAC10.html)
BR (1) BR112021013415A2 (cg-RX-API-DMAC10.html)
CA (1) CA3125748A1 (cg-RX-API-DMAC10.html)
IL (1) IL284679A (cg-RX-API-DMAC10.html)
MX (1) MX2021008207A (cg-RX-API-DMAC10.html)
SG (1) SG11202107454UA (cg-RX-API-DMAC10.html)
WO (1) WO2020146423A1 (cg-RX-API-DMAC10.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2916217T3 (es) 2017-01-05 2022-06-29 Kahr Medical Ltd Una proteína de fusión SIRP1 ALPHA-41BBL y métodos de uso de la misma
DK3565579T3 (da) 2017-01-05 2023-09-04 Kahr Medical Ltd Pd1-41bbl-fusionsprotein og fremgangsmåder til anvendelse deraf
US11299530B2 (en) 2017-01-05 2022-04-12 Kahr Medical Ltd. SIRP alpha-CD70 fusion protein and methods of use thereof
US11566060B2 (en) 2017-01-05 2023-01-31 Kahr Medical Ltd. PD1-CD70 fusion protein and methods of use thereof
IL280102B1 (en) 2018-07-11 2026-07-01 Kahr Medical Ltd Fusion protein containing PD1-4-1BBL and methods of using the same
CA3104780A1 (en) 2018-07-11 2020-01-16 Kahr Medical Ltd. Sirpalpha-4-1bbl variant fusion protein and methods of use thereof
CN113518823B (zh) 2019-01-07 2025-05-02 托马斯杰斐逊大学 多功能的融合蛋白及其用途
EP4175656A4 (en) * 2020-07-03 2024-10-16 The Trustees of Columbia University in the City of New York POLYFUNCTIONAL ORTHOGONAL PROTEIN CHIMERA
US20240076346A1 (en) * 2021-01-13 2024-03-07 Kahr Medical Ltd. Type i membrane proteins heterodimers and methods of use thereof
WO2022188129A1 (zh) * 2021-03-12 2022-09-15 利时雨 广谱趋化因子受体抑制剂增强新冠肺炎病毒感染的细胞免疫的分子机制及在其药物防治中的应用
CN118369336A (zh) * 2022-04-15 2024-07-19 Im生技股份有限公司 具有改进半衰期的融合蛋白平台

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017162797A1 (en) * 2016-03-23 2017-09-28 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Fusion proteins of pd-1 and 4-1bb

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001056591A1 (en) 2000-02-03 2001-08-09 Thomas Jefferson University vMIP-II PEPTIDE ANTAGONISTS OF CXCR4
US7897152B2 (en) * 2000-09-18 2011-03-01 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Viral chemokine-antigen fusion proteins
US8021658B2 (en) * 2001-05-25 2011-09-20 Thomas Jefferson University Alternative splice forms of proteins as basis for multiple therapeutic modalities
CN105837690A (zh) 2006-06-12 2016-08-10 新兴产品开发西雅图有限公司 具有效应功能的单链多价结合蛋白
DE102009047243A1 (de) 2009-11-27 2011-06-01 Orgentec Diagnostika Gmbh Monospezifische Polypeptidreagenzien
EP2950814A4 (en) 2013-01-31 2016-06-08 Univ Jefferson FUSION PROTEINS BASED ON PD-L1 AND PD-L2 AND USES THEREOF
EP3030322A2 (en) 2013-08-05 2016-06-15 Cambridge Enterprise Limited Inhibition of cxcr4 signaling in cancer immunotherapy
US20180179282A1 (en) 2015-06-12 2018-06-28 Bristol-Myers Squibb Company Treatment of cancer by combined blockade of the pd-1 and cxcr4 signaling pathways
CN109608544B (zh) * 2015-11-17 2022-09-16 苏州盛迪亚生物医药有限公司 Pd-l1抗体、其抗原结合片段及其医药用途
GB201521383D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl And Ucb Celltech Method
JP6732915B2 (ja) * 2015-12-15 2020-07-29 ギリアード サイエンシーズ, インコーポレイテッド ヒト免疫不全ウイルス中和抗体
US11124577B2 (en) * 2016-11-02 2021-09-21 Engmab Sàrl Bispecific antibody against BCMA and CD3 and an immunological drug for combined use in treating multiple myeloma
RU2665790C1 (ru) 2017-04-17 2018-09-04 Закрытое Акционерное Общество "Биокад" Моноклональное антитело к pd-l1
WO2018209017A1 (en) * 2017-05-10 2018-11-15 The General Hospital Corporation Cancer treatment with a cxcl12 signaling inhibitor and an immune checkpoint inhibitor
RU2766590C2 (ru) * 2017-05-16 2022-03-15 Цзянсу Хэнжуй Медисин Ко., Лтд. Фармацевтическая композиция на основе антитела к pd-l1 и ее применение
US20200140547A1 (en) * 2017-05-26 2020-05-07 The Johns Hopkins University Multifunctional antibody-ligand traps to modulate immune tolerance
GB201709808D0 (en) * 2017-06-20 2017-08-02 Kymab Ltd Antibodies
JP7009517B2 (ja) 2017-06-21 2022-01-25 ギリアード サイエンシーズ, インコーポレイテッド Hiv gp120およびcd3を標的とする多重特異性抗体
CN113518823B (zh) 2019-01-07 2025-05-02 托马斯杰斐逊大学 多功能的融合蛋白及其用途

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017162797A1 (en) * 2016-03-23 2017-09-28 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Fusion proteins of pd-1 and 4-1bb

Also Published As

Publication number Publication date
AU2020207265B2 (en) 2026-03-26
CN113518823A (zh) 2021-10-19
JP2022528030A (ja) 2022-06-08
CA3125748A1 (en) 2020-07-16
EP3908664A4 (en) 2023-01-25
US20220056102A1 (en) 2022-02-24
BR112021013415A2 (pt) 2021-12-28
JP7587505B2 (ja) 2024-11-20
KR20220025698A (ko) 2022-03-03
MX2021008207A (es) 2021-11-04
EP3908664A1 (en) 2021-11-17
AU2026204884A1 (en) 2026-07-09
US20260193312A1 (en) 2026-07-09
SG11202107454UA (en) 2021-08-30
KR20260116815A (ko) 2026-07-28
IL284679A (en) 2021-08-31
KR102996287B1 (ko) 2026-07-24
WO2020146423A1 (en) 2020-07-16
AU2020207265A1 (en) 2021-08-12
US12497439B2 (en) 2025-12-16

Similar Documents

Publication Publication Date Title
AU2020207265B2 (en) Multi-functional fusion proteins and uses thereof
US11827697B2 (en) Anti-PD-1/anti-VEGF natural antibody structure like heterodimeric form bispecific antibody and preparation thereof
US20230227584A1 (en) Bispecific antibodies comprising a modified c-terminal crossfab fragment
JP7148539B2 (ja) 免疫抱合体
JP7675083B2 (ja) 新規4-1bbl三量体含有抗原結合分子
JP2023056001A (ja) Tgf-b-受容体外部ドメイン融合分子及びその使用
US20190119387A1 (en) Inhibition of tgfbeta in immunotherapy
CA3140055A1 (en) Nk cell-directed chimeric proteins
US20220259281A1 (en) Chimeric protein expressing t-cells
US20250115657A1 (en) Bispecific FC Fusion Proteins with sPD-1 and IL-15
KR102666554B1 (ko) ErbB3 특이적인 키메라 항원 수용체 및 이를 발현하는 면역세포 치료제
RU2815388C2 (ru) Многофункциональные слитые белки и их применения
US9920119B2 (en) Chimeric molecule involving oligomerized FasL extracellular domain
HK40060282A (en) Multi-functional fusion proteins and uses thereof
HK40112638A (en) Bispecific fc fusion proteins with spd-1 and il-15
HK1163129A (en) Cd86 antagonist multi-target binding proteins

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40060282

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant